Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Mo | Autonomix Medical, Inc. Treats First Patient in Follow-On Market Expansion Phase ("PoC 2") of Proof-of-Concept Human Clinical Study | 86 | GlobeNewswire (Europe) | Expansion of study into additional indications doubles the potential addressable market beyond pancreatic cancer pain PoC 2 phase builds on early success and positive results demonstrated in PoC 1... ► Artikel lesen | |
Fr | Autonomix erhält US-Patent für nervensensitive Medizintechnologie | 5 | Investing.com Deutsch | ||
Fr | Autonomix receives US patent for nerve-sensing medical technology | 1 | Investing.com | ||
Fr | Autonomix Medical, Inc. Granted New U.S. Patent for Innovative Catheter-Based Platform Technology | 360 | GlobeNewswire (Europe) | Patent supports the Company's broader mission to advance minimally invasive, nerve-focused treatments across high-need indications Strengthens strategic position in a multi-billion-dollar market opportunity... ► Artikel lesen | |
05.06. | Autonomix set to expand cancer pain treatment trial | 2 | Investing.com | ||
AUTONOMIX MEDICAL Aktie jetzt für 0€ handeln | |||||
05.06. | Autonomix erweitert klinische Studie zur Behandlung von Krebsschmerzen | - | Investing.com Deutsch | ||
05.06. | Autonomix Medical, Inc. Granted Approval to Expand Proof-of-Concept Human Clinical Study, Doubling Potential Addressable Market Beyond Pancreatic Cancer Pain | 4 | GlobeNewswire (USA) | ||
29.05. | Autonomix Medical, Inc. - 10-K, Annual Report | 2 | SEC Filings | ||
22.05. | AMIX Stock May Climb Following Key U.S. Patent for Nerve-Sensing Tech | 2 | Zacks | ||
16.05. | Autonomix picks up key nerve ablation catheter patent | 1 | MassDevice | ||
14.05. | Autonomix Medical, Inc.: Autonomix CEO Brad Hauser to Present at Virtual Investor's Closing Bell Event | 1 | GlobeNewswire (USA) | ||
13.05. | Autonomix plans expansion phase for cancer pain trial | 2 | Investing.com | ||
13.05. | Brad Hauser, CEO of Autonomix Medical, Inc. Outlines Follow-On Expansion Study Expected to Begin in Q2 2025, Potentially Doubling Addressable Market | 236 | GlobeNewswire (Europe) | Discussion in Virtual Investor CEO Connect focuses on Company's planned follow-on market expansion study phase ("PoC 2") of proof-of-concept trial; Access Here Additional indications potentially double... ► Artikel lesen | |
05.05. | Autonomix reports significant pain relief in cancer trial | 2 | Investing.com | ||
05.05. | Autonomix Medical, Inc.: Autonomix Highlights Compelling Patient Testimonial Showing Rapid Pain Relief from First-in-Human Proof-of-Concept Trial in Pancreatic Cancer Pain | 212 | GlobeNewswire (Europe) | Video testimonial demonstrates pain reduction after transvascular nerve ablation, suggesting potential for improving quality of life in late-stage cancer care Patient testimonial now available here... ► Artikel lesen | |
01.05. | Autonomix Medical, Inc. (NASDAQ: AMIX) Participates in Virtual Investor "What This Means" Segment Highlighting Key Learnings from First-In-Human Trial and Extension into Visceral Cancer Pain | 1 | GlobeNewswire (USA) | ||
30.04. | Autonomix Medical Reports Positive Results In First Human Trial For Cancer Pain, Stock Down | 1 | RTTNews | ||
30.04. | Autonomix erzielt Fortschritte bei Schmerzbehandlung in Krebsstudien | 2 | Investing.com Deutsch | ||
30.04. | Autonomix advances pain treatment in cancer trials | 1 | Investing.com | ||
30.04. | Autonomix Medical, Inc. Reports Positive Outcomes in Initial Phase of First-in-Human Proof-of-Concept Trial in Pancreatic Cancer Pain and Initiates Market Expansion Study for Visceral Cancer Pain | 112 | GlobeNewswire (Europe) | Initial trial phase ("PoC 1") achieved key learnings and met all study objectives Clinically meaningful pain reduction with 100% of responders achieving zero opioid use at 7 days post-procedure and... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
SIEMENS HEALTHINEERS | 47,420 | +1,07 % | JEFFERIES stuft Siemens Healthineers auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Siemens Healthineers vor Zahlen auf "Buy" mit einem Kursziel von 60 Euro belassen. Julien Dormois fasste in einer am Donnerstag... ► Artikel lesen | |
FRESENIUS | 42,280 | -0,84 % | Aktienmarkt: Fresenius SE & Co. KGaA-Aktie kann sich nicht behaupten (42,16 €) | Der Anteilsschein von Fresenius SE & Co. KGaA notiert am Mittwoch leichter. Die Aktie kostete zuletzt 42,16 Euro. Für Inhaber von Fresenius+Co KgaA ist der heutige Handelstag bisher nicht sonderlich... ► Artikel lesen | |
FRESENIUS MEDICAL CARE | 48,320 | -0,98 % | UBS stuft FMC FRESENIUS MEDICAL CARE AG auf 'Neutral' | ZÜRICH (dpa-AFX Analyser) - Die Schweizer Großbank UBS hat FMC auf "Neutral" belassen. In Gesprächen mit Investoren in Europa habe er ein gestiegenes Interesse an Medizintechnikunternehmen festgestellt... ► Artikel lesen | |
PROCEPT BIOROBOTICS | 58,18 | +2,76 % | PROCEPT BioRobotics Reports Fourth Quarter and Full Year 2024 Results | SAN JOSE, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (Nasdaq: PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative... ► Artikel lesen | |
GERRESHEIMER | 48,740 | +0,99 % | Gerresheimer-Aktie: Bleibt die Übernahmefantasie? | Die Gerresheimer-Aktie musste zuletzt heftige Kursverluste hinnehmen. Am Donnerstag verbessert sie sich leicht und steht aktuell bei 47,30 €. Die Ursache für die hohen Kursschwankungen waren Nachrichten... ► Artikel lesen | |
CARL ZEISS MEDITEC | 56,60 | +0,27 % | UBS stuft CARL ZEISS MEDITEC AG auf 'Neutral' | ZÜRICH (dpa-AFX Analyser) - Die Schweizer Großbank UBS hat Carl Zeiss Meditec auf "Neutral" belassen. In Gesprächen mit Investoren in Europa habe er ein gestiegenes Interesse an Medizintechnikunternehmen... ► Artikel lesen | |
CAPSOVISION | 3,500 | 0,00 % | CapsoVision Prices IPO Of 5.50 Mln Shares At $5.00/shr | WASHINGTON (dpa-AFX) - CapsoVision Inc. (CV), a commercial-stage medical technology company that develops
advanced imaging and artificial intelligence technologies that are deployed in its... ► Artikel lesen | |
UNITEDHEALTH | 260,90 | -5,66 % | United-Health-Konkurrent: Kaufchance? Diese Aktie ist einfach viel zu billig! | © Foto: Google GeminiDie Aktie des US-Krankenversicherers Centene ist so günstig wie lange nicht. Das gilt nicht nur für die Aktie, sondern auch die Bewertung des Unternehmens.In der US-Krankenversicherungsbranche... ► Artikel lesen | |
CENTENE | 28,745 | -40,15 % | Centene-Aktie läuft heute schlechter (46,0076 €) | Im Minus liegt aktuell der Anteilsschein von Centene . Die Aktie kostete zuletzt 53,62 US-Dollar. Ein Preisabschlag in Höhe von 43 Cent müssen derzeit die Aktionäre von Centene hinnehmen. Für das Papier... ► Artikel lesen | |
BRIGHTSPRING HEALTH SERVICES | 22,010 | -1,17 % | BrightSpring Health Leads Companies In Line For Triple-Digit Profit Growth | ||
ALIGNMENT HEALTHCARE | 13,610 | -4,15 % | Alignment Healthcare Reports Strong First Quarter 2025 Results; Exceeds High-End of Expectations On 4 Critical KPIs; Raises Midpoint of 2025 Guidance; Announces CFO Transition | Delivers Q1 revenue of $926.9 million, up 47.5% year over year, and grows Medicare Advantage (MA) membership by 31.7% to approximately 217,500 membersExceeds high-end of Q1 guidance on membership... ► Artikel lesen | |
MIMEDX | 6,230 | -0,24 % | MiMedx Group, Inc: MIMEDX Announces First Quarter 2025 Operating and Financial Results | Net Sales of $88 million Grew 4% Year-Over-Year for the First Quarter First Quarter GAAP Net Income and Earnings Per Share were $7 Million and $0.05, Respectively First Quarter Adjusted EBITDA... ► Artikel lesen | |
PHETON | 18,380 | +0,27 % | Pheton Holdings Ltd - S-8, Securities to be offered to employees in employee benefit plans | ||
NUTEX HEALTH | 122,29 | -7,36 % | Nutex Health, Inc.: Nutex Health Reports First Quarter 2025 Financial Results | TOTAL REVENUE OF $211.8 MILLION VERSUS $67.5 MILLION IN Q1 2024, AN INCREASE OF 213.8%
NET INCOME ATTRIBUTABLE TO NUTEX HEALTH INC. OF $14.6 MILLION VERSUS NET... ► Artikel lesen | |
GENEDX | 89,79 | -0,55 % | Expert Outlook: GeneDx Holdings Through The Eyes Of 4 Analysts |